Human antibodies against amyloid β peptide: A potential treatment for Alzheimer's disease

Richard Dodel, Harald Hampel, Candan Depboylu, Suizhen Lin, Feng Gao, Sabine Schock, Steffi Jäckel, Xing Wei, Katharina Buerger, Christine Höft, Bernhard Hemmer, Hans Jürgen Möller, Martin Farlow, Wolfgang H. Oertel, Norbert Sommer, Yansheng Du

Research output: Contribution to journalArticle

137 Citations (Scopus)

Abstract

Naturally occurring antibodies directed against β-amyloid (Aβ) were detected in intravenous immunoglobulin preparations. After intravenous immunoglobulin treatment in patients with different neurological diseases, total Aβ and Aβ1-42 in the cerebrospinal fluid was reduced significantly compared with baseline values. In the serum, total Aβ levels increased after intravenous immunoglobulin treatment, whereas no significant change was observed in Aβ1-42 levels. Antibodies against Aβ were found to be increased in the serum and cerebrospinal fluid after intravenous immunoglobulin treatment. This study provides evidence that intravenous immunoglobulin or purified Aβ antibodies may modify Aβ and Aβ1-42 levels, suggesting potential utility as a therapy for Alzheimer disease.

Original languageEnglish
Pages (from-to)253-256
Number of pages4
JournalAnnals of Neurology
Volume52
Issue number2
DOIs
StatePublished - 2002

Fingerprint

Intravenous Immunoglobulins
Amyloid
Alzheimer Disease
Antibodies
Cerebrospinal Fluid
Therapeutics
Serum
peptide A

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Human antibodies against amyloid β peptide : A potential treatment for Alzheimer's disease. / Dodel, Richard; Hampel, Harald; Depboylu, Candan; Lin, Suizhen; Gao, Feng; Schock, Sabine; Jäckel, Steffi; Wei, Xing; Buerger, Katharina; Höft, Christine; Hemmer, Bernhard; Möller, Hans Jürgen; Farlow, Martin; Oertel, Wolfgang H.; Sommer, Norbert; Du, Yansheng.

In: Annals of Neurology, Vol. 52, No. 2, 2002, p. 253-256.

Research output: Contribution to journalArticle

Dodel, R, Hampel, H, Depboylu, C, Lin, S, Gao, F, Schock, S, Jäckel, S, Wei, X, Buerger, K, Höft, C, Hemmer, B, Möller, HJ, Farlow, M, Oertel, WH, Sommer, N & Du, Y 2002, 'Human antibodies against amyloid β peptide: A potential treatment for Alzheimer's disease', Annals of Neurology, vol. 52, no. 2, pp. 253-256. https://doi.org/10.1002/ana.10253
Dodel, Richard ; Hampel, Harald ; Depboylu, Candan ; Lin, Suizhen ; Gao, Feng ; Schock, Sabine ; Jäckel, Steffi ; Wei, Xing ; Buerger, Katharina ; Höft, Christine ; Hemmer, Bernhard ; Möller, Hans Jürgen ; Farlow, Martin ; Oertel, Wolfgang H. ; Sommer, Norbert ; Du, Yansheng. / Human antibodies against amyloid β peptide : A potential treatment for Alzheimer's disease. In: Annals of Neurology. 2002 ; Vol. 52, No. 2. pp. 253-256.
@article{3786b4ccf8684c40972de9a1d64894c8,
title = "Human antibodies against amyloid β peptide: A potential treatment for Alzheimer's disease",
abstract = "Naturally occurring antibodies directed against β-amyloid (Aβ) were detected in intravenous immunoglobulin preparations. After intravenous immunoglobulin treatment in patients with different neurological diseases, total Aβ and Aβ1-42 in the cerebrospinal fluid was reduced significantly compared with baseline values. In the serum, total Aβ levels increased after intravenous immunoglobulin treatment, whereas no significant change was observed in Aβ1-42 levels. Antibodies against Aβ were found to be increased in the serum and cerebrospinal fluid after intravenous immunoglobulin treatment. This study provides evidence that intravenous immunoglobulin or purified Aβ antibodies may modify Aβ and Aβ1-42 levels, suggesting potential utility as a therapy for Alzheimer disease.",
author = "Richard Dodel and Harald Hampel and Candan Depboylu and Suizhen Lin and Feng Gao and Sabine Schock and Steffi J{\"a}ckel and Xing Wei and Katharina Buerger and Christine H{\"o}ft and Bernhard Hemmer and M{\"o}ller, {Hans J{\"u}rgen} and Martin Farlow and Oertel, {Wolfgang H.} and Norbert Sommer and Yansheng Du",
year = "2002",
doi = "10.1002/ana.10253",
language = "English",
volume = "52",
pages = "253--256",
journal = "Annals of Neurology",
issn = "0364-5134",
publisher = "John Wiley and Sons Inc.",
number = "2",

}

TY - JOUR

T1 - Human antibodies against amyloid β peptide

T2 - A potential treatment for Alzheimer's disease

AU - Dodel, Richard

AU - Hampel, Harald

AU - Depboylu, Candan

AU - Lin, Suizhen

AU - Gao, Feng

AU - Schock, Sabine

AU - Jäckel, Steffi

AU - Wei, Xing

AU - Buerger, Katharina

AU - Höft, Christine

AU - Hemmer, Bernhard

AU - Möller, Hans Jürgen

AU - Farlow, Martin

AU - Oertel, Wolfgang H.

AU - Sommer, Norbert

AU - Du, Yansheng

PY - 2002

Y1 - 2002

N2 - Naturally occurring antibodies directed against β-amyloid (Aβ) were detected in intravenous immunoglobulin preparations. After intravenous immunoglobulin treatment in patients with different neurological diseases, total Aβ and Aβ1-42 in the cerebrospinal fluid was reduced significantly compared with baseline values. In the serum, total Aβ levels increased after intravenous immunoglobulin treatment, whereas no significant change was observed in Aβ1-42 levels. Antibodies against Aβ were found to be increased in the serum and cerebrospinal fluid after intravenous immunoglobulin treatment. This study provides evidence that intravenous immunoglobulin or purified Aβ antibodies may modify Aβ and Aβ1-42 levels, suggesting potential utility as a therapy for Alzheimer disease.

AB - Naturally occurring antibodies directed against β-amyloid (Aβ) were detected in intravenous immunoglobulin preparations. After intravenous immunoglobulin treatment in patients with different neurological diseases, total Aβ and Aβ1-42 in the cerebrospinal fluid was reduced significantly compared with baseline values. In the serum, total Aβ levels increased after intravenous immunoglobulin treatment, whereas no significant change was observed in Aβ1-42 levels. Antibodies against Aβ were found to be increased in the serum and cerebrospinal fluid after intravenous immunoglobulin treatment. This study provides evidence that intravenous immunoglobulin or purified Aβ antibodies may modify Aβ and Aβ1-42 levels, suggesting potential utility as a therapy for Alzheimer disease.

UR - http://www.scopus.com/inward/record.url?scp=0036327185&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036327185&partnerID=8YFLogxK

U2 - 10.1002/ana.10253

DO - 10.1002/ana.10253

M3 - Article

C2 - 12210803

AN - SCOPUS:0036327185

VL - 52

SP - 253

EP - 256

JO - Annals of Neurology

JF - Annals of Neurology

SN - 0364-5134

IS - 2

ER -